The mean decreases in fasting plasma glucose from baseline to endpoint were significantly greater for all three rGLP-1 dose groups than for the placebo group , with the greatest decrease occurring in the 5.0 pkm dose group ( -26.0 mg/dl , s.d. 8.5 , p = 0.02 ) .